Ergoteles LLC Eagle Pharmaceuticals, Inc. Transaction History

Ergoteles LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$17.74 - $31.87 $471,848 - $847,678	26,598 Added 62.32%	69,275 $1.35 Million
Q1 2023 May 10, 2023	BUY	$25.06 - $34.09 $779,541 - $1.06 Million	31,107 Added 268.86%	42,677 $1.21 Million
Q4 2022 Feb 14, 2023	BUY	$24.98 - $39.77 $289,018 - $460,138	11,570 New	11,570 $338,000
Q2 2022 Aug 12, 2022	BUY	$41.26 - $51.35 $912,588 - $1.14 Million	22,118 Added 94.05%	45,636 $2.03 Million
Q1 2022 May 13, 2022	BUY	$44.58 - $52.6 $1.05 Million - $1.24 Million	23,518 New	23,518 $1.16 Million
Q1 2021 May 12, 2021	SELL	$40.32 - $50.97 $286,272 - $361,887	-7,100 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$41.72 - $51.34 $296,212 - $364,514	7,100 New	7,100 $331,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.